Zealand Pharma A/S (OTCMKTS:ZLDPF) Raised to Hold at William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by investment analysts at William Blair to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

ZLDPF has been the subject of several other reports. JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company. Cantor Fitzgerald raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st.

Zealand Pharma A/S Trading Down 0.7 %

OTCMKTS ZLDPF opened at $97.78 on Thursday. The company’s 50-day moving average price is $101.00 and its 200-day moving average price is $112.64. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The stock has a market cap of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. Zealand Pharma A/S has a 12 month low of $80.86 and a 12 month high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $28.11 million. Equities research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.